Create Biomarker Confidence with Tissue Context
Flagship’s cTA® Platform and Decision Support Process accelerates your biomarker-driven drug development strategies.
A comprehensive catalog of more than 100 singleplex and multiplex brightfield immunohistochemistry assays that provide actionable data to define and advance your biomarker program.
Rapidly evaluate existing targets through trend analysis, tissue wide expression and relative rank ordering. Accelerate and simplify your current and future tissue analysis needs.
Flagship Biosciences Accelerates Your Path to Clinical Success
Discovery & PhI Trials
Make informed early pipeline decisions that will accelerate the right clinical path.
Enable critical go/no-go decisions based on confirmation of action.
PhII - PhIII Trials
Solve critical problems in experimental medicine that pose barriers to success.
Differentiate your commercial strategy and increase probability of success.
Meeting the challenges of biomarkers
73% of oncology compounds rely on biomarker data during development, with the scientific challenges of biomarker identification and test development being the most challenging.
Immune Response Characterization for Effective Therapies
Flagship Biosciences’ cTA® platform and precision decision support processes apply computational analysis to tissue biomarkers to help drug developers confidently define a path to success.
SOLVE DIFFICULT TISSUE ANALYSIS CHALLENGES WITH OUR UNIQUE APPROACH
Work With Us
Breadth and depth in people and technology to deliver on any challenge
Work With Us